ALAN-RE (Aptamer Linked Anti Nucleolin – Radiation Enhancement) is an aptamer-based investigational drug candidate currently under development and evaluation to be used in combination with radiation therapy to treat virtually any type of cancer. The gold nanoparticle component of this drug candidate enhances radiation therapy by “magnifying” the effects of radiation on the targeted tumor cells. Because of this beneficial effect, lower doses of radiation can be used, resulting in fewer side effects for patients undergoing radiation therapy for their cancers.